Barclays analyst Luke Sergott lowered the firm’s price target on PacBio (PACB) to $1.50 from $2 and keeps an Equal Weight rating on the shares. The shares ran up in early June following upbeat commentary at a conference, which creates a relatively higher bar for second half of 2025 numbers, the analyst tells investors in a research note. This makes Barclays more cautious given the “tough” National Institutes of Health funding environment.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACB:
- Largest borrow rate increases among liquid names
- Pacific Biosciences Approves Key Proposals at Annual Meeting
- PacBio partners with Target ALS to launch genome sequencing initiative
- Hold Recommendation for Pacific Biosciences Amid Mixed Performance and Market Challenges
- PacBio appoints Haorui Gene as official distributor in China